Profile
Scott D.
Kelley served as Vice President & Medical Director at Aspect Medical Systems, Inc. from 2000 to 2011.
Prior to that, he was an Associate Professor & Director-Liver Transplant at The University of California, San Francisco from 1990 to 2000.
He also served as Chief Medical Officer at Flexion Therapeutics, Inc. from 2017 to 2021.
In addition, he held a position as Vice President-Medical Affairs at Sanofi Corp.
Dr. Kelley received his undergraduate and graduate degrees from Stanford University and his doctorate from The University of California, San Francisco in 1984.
Former positions of Scott D. Kelley
| Companies | Position | End |
|---|---|---|
| FLEXION THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2021-05-30 |
| The University of California, San Francisco | Corporate Officer/Principal | 1999-12-31 |
| Sanofi Corp. | Corporate Officer/Principal | - |
Aspect Medical Systems, Inc.
 Aspect Medical Systems, Inc. Medical SpecialtiesHealth Technology Aspect Medical Systems, Inc. developed and manufactured anesthesia monitoring system that was called Bispectral (BIS) system. The company was founded in 1987 and was headquartered in Norwood, MA. | Chief Tech/Sci/R&D Officer | - |
Training of Scott D. Kelley
| Stanford University | Graduate Degree |
| The University of California, San Francisco | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 3 |
|---|---|
Aspect Medical Systems, Inc.
Aspect Medical Systems, Inc. Medical SpecialtiesHealth Technology Aspect Medical Systems, Inc. developed and manufactured anesthesia monitoring system that was called Bispectral (BIS) system. The company was founded in 1987 and was headquartered in Norwood, MA. | Health Technology |
Flexion Therapeutics, Inc.
 Flexion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA. | Health Technology |
| Sanofi Corp. |
- Stock Market
- Insiders
- Scott D. Kelley
